|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
These trials studied SGLT2 inhibitors (dapagliflozin and empagliflozin) and a dual SGLT1 and SGLT2 inhibitor (sotagliflozin), and demonstrated that these oral non-insulin antihyperglycaemic medications are able not only to improve glycaemic control, but also to reduce body weight and extend time in range without increasing rates of hypoglycaemia in type 1 diabetes.
|
31183975 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
We hypothesize that micafungin may inhibit SGLT-1 function and decrease insulin requirements in patient with T1DM.
|
30398618 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Sotagliflflozin (SOTA), as a dual SGLT-1/2 inhibitor, has the potential to be the first oral antidiabetic drug (OAD) to be approved for T1DM in the US market.
|
31415414 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials.
|
30967375 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
The objective of this study was to evaluate the efficacy and safety of the dual sodium-glucose cotransporter 1 and 2 inhibitor sotagliflozin compared with placebo when combined with optimized insulin in adults with type 1 diabetes (T1D).
|
29937431 |
2018 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Evaluate the efficacy and safety of the dual sodium-glucose cotransporter 1 (SGLT1) and SGLT2 inhibitor sotagliflozin in combination with optimized insulin in type 1 diabetes (T1D).
|
29937430 |
2018 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this review, the authors discuss the efficacy and safety of non-insulin therapies, including pramlintide, glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 inhibitors (DPP-4), sodium-glucose cotransporter (SGLT1 and SGLT2) inhibitors, metformin, sulfonylureas, and thiazolidinediones as add-on therapies to insulin in T1D.
|
29991320 |
2018 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
To identify and evaluate the recent trials of sodium-glucose cotransporter 1 and 2 (SGLT1 and SGLT2, respectively) inhibitor use in patients with type 1 diabetes (T1D).
|
29794497 |
2018 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In animal model of type 1 diabetes, the expression of Sglt1 transporter is significantly decreased, and in the animal model of type 2 diabetes it is significantly increased.
|
28034463 |
2017 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We have examined the effects of streptozotocin-induced type 1 diabetes on the expression and subcellular distribution of the classic sugar transporters (GLUT-1 to 5 and sodium-dependent glucose transporter-1 [SGLT-1]) in the endothelial cells of an en face preparation of septal coronary artery from Wistar rats.
|
15662550 |
2004 |